Amendments to the claims:

Please cancel claims 1-4 and 14-16. Please also re-write claim 5 in independent form as indicated below. This listing of claims replaces all earlier versions of the claims in the application.

Claims 1-4 (Canceled)

5. (Currently Amended) An aqueous intravenous infusion solution comprising levosimendan or a salt thereof as an active ingredient, the pH-value of the solution being lower than 5, and a solubility enhancing agent ~~A solution according to claim 3~~ ,wherein the solubility enhancing agent is polyvinylpyrrolidone or ethanol.

6. (Previously Presented) A pharmaceutical solution, comprising

(a) levosimendan or a pharmaceutically acceptable salt thereof as an active ingredient,

(b) a pharmaceutically acceptable organic solvent comprising ethanol,

(c) a stability enhancing amount of a pharmaceutically acceptable organic acid having pKa in the range of from 2 to 4, and optionally

(d) a water-solubility enhancing agent.

7. (Previously Presented) A solution according to claim 6, wherein the amount of said solvent is 90-99.9% by weight of the solution.

8. (Previously Presented) A solution according to claim 6, wherein the amount of said organic acid is 0.005-2% by weight of the solution.

9. (Previously Presented) A solution according to claim 6, wherein the pharmaceutically acceptable organic acid is a 2-hydroxy alkanoic acid.

10. (Previously Presented) A solution according to claim 9, wherein the pharmaceutically acceptable organic acid is citric acid, lactic acid, tartaric acid or malic acid.

11. (Original) A solution according to claim 6, wherein the amount of the water-solubility enhancing agent is 0.1 - 5% by weight.

12. (Original) A solution according to claim 6, wherein the water-solubility enhancing agent is polyvinylpyrrolidone.

13. (Previously Presented) A solution according to claim 6, comprising

(a) levosimendan or a pharmaceutically acceptable salt thereof in an amount of 0.01-1.0% by weight,

(b) dehydrated ethanol in an amount of 95-99.5% by weight,

(c) citric acid in an amount of 0.03-0.6% by weight, and

(d) polyvinylpyrrolidone in an amount of 0.5-2% by weight.

Claims 14-16 (Canceled)

17. (Previously Presented) A solution according to claim 6, wherein the solution is an intravenous infusion concentrate.

18. (Previously Presented) A solution according to claim 6, wherein the amount of said solvent is 95-99.9% by weight of the solution.

19. (Previously Presented) A solution according to claim 6, wherein the amount of said organic acid is 0.01-1% by weight of the solution.

20. (Previously Presented) A solution according to claim 7, wherein the amount of said organic acid is 0.005-2% by weight of the solution.

21. (Previously Presented) A solution according to claim 7, wherein the amount of said organic acid is 0.01-1% by weight of the solution.